Cukrzyca opis choroby Część 1

8203 Views
Was this article interesting to you?

Scientific Sources

What is diabetes and how common is it?

Diabetes is a metabolic disorder characterized by elevated blood glucose levels. Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells, while Type 2 diabetes involves insulin resistance and progressive beta cell dysfunction. Diabetes affects hundreds of millions worldwide and leads to serious complications including cardiovascular disease, kidney failure, blindness, and neuropathy.

What causes Type 2 diabetes?

Type 2 diabetes develops from combination of insulin resistance (cells become less responsive to insulin) and progressive beta cell failure (pancreas produces less insulin over time). Risk factors include obesity, sedentary lifestyle, poor diet, genetics, and age. The disease progresses through stages: prediabetes (impaired glucose tolerance) to overt diabetes with fasting glucose>126mg/dL or HbA1c>6.5%.

What are diabetes complications?

Diabetes complications affect multiple organ systems. Microvascular: retinopathy (leading cause of blindness in working-age adults), nephropathy (leading cause of kidney failure), neuropathy (nerve damage affecting 50% of patients). Macrovascular: 2-4x increased cardiovascular disease risk, stroke, peripheral arterial disease. Complications result from chronic hyperglycemia damaging blood vessels and nerves.

Can Type 2 diabetes be prevented?

Yes. Landmark prevention trials show lifestyle intervention (diet, exercise, weight loss) reduces diabetes development by 58% in high-risk individuals with prediabetes. Even modest weight loss (7% of body weight) significantly reduces risk. Early intervention during prediabetes stage offers best prevention opportunity.

What is HbA1c and why does it matter?

HbA1c (glycated hemoglobin) measures average blood glucose over 2-3 months. Normal: <5.7%. Prediabetes: 5.7-6.4%. Diabetes: ≥6.5%. Each 1% reduction in HbA1c reduces microvascular complications by 37% and cardiovascular events by 14%. Target HbA1c for most diabetics: <7%, though individualized based on patient factors.

Clinical Benefits & Efficacy Data

  • Lifestyle intervention (diet + exercise) prevents diabetes development by 58% in prediabetic individuals over 3-4 years
  • Weight loss (7% body weight) reduces diabetes risk by 50-60% and improves insulin sensitivity by 40-70%
  • Each 1% HbA1c reduction decreases microvascular complications by 37% and cardiovascular events by 14%
  • Mediterranean diet reduces diabetes incidence by 52% compared to low-fat diet in prevention trials
  • Physical activity (150 min/week moderate exercise) improves insulin sensitivity by 40-50% and glucose control
  • Early intervention in prediabetes can delay or prevent progression to overt diabetes in 40-70% of cases
  • Comprehensive diabetes management reduces all-cause mortality by 30-40% compared to poor glycemic control
  1. Medical management: Continue prescribed diabetes medications, monitor glucose regularly
  2. Lifestyle: 7% weight loss goal if overweight, 150 min/week physical activity
  3. Diet: Mediterranean-style eating pattern, reduce refined carbohydrates
  4. Monitor: HbA1c every 3 months, target <7% (individualized)
  5. Complications screening: Annual eye, kidney, foot exams
  6. Work with diabetes team for comprehensive management
  • Type 2 diabetes (ICD-10: E11.9)
  • Prediabetes/impaired glucose tolerance (ICD-10: R73.03)
  • Type 1 diabetes (ICD-10: E10.9)
  • Metabolic syndrome (ICD-10: E88.81)
  • Those at high risk for diabetes (family history, obesity)
  • Those expecting supplements to replace diabetes medications
  • Diabetic ketoacidosis requiring immediate medical intervention
  • Hypoglycemia-prone patients changing interventions without medical supervision
  • Pregnant women with gestational diabetes without obstetric oversight

Clinical Evidence & Study Results

Diabetes Prevention Program - Landmark Trial

Study Design: Randomized controlled trial in 3,234 adults with prediabetes (impaired glucose tolerance). Arms: intensive lifestyle intervention vs metformin vs placebo. Follow-up: 2.8 years.

Results: Diabetes incidence: Lifestyle intervention reduced by 58% vs placebo (p<0.001). Metformin reduced by 31% vs placebo. Lifestyle intervention superior to metformin (p<0.001). Weight loss: Lifestyle group lost 7% body weight (5.6kg average). Insulin sensitivity: 58% improvement in lifestyle group vs 31% metformin. Long-term follow-up (10 years): Sustained 34% risk reduction in lifestyle group. Cost-effectiveness: $8,800 per quality-adjusted life-year for lifestyle intervention.

Conclusion: Lifestyle intervention represents most effective diabetes prevention strategy, superior to pharmacotherapy.

Citation: Knowler WC et al. N Engl J Med. 2002 Feb 7;346(6):393-403

UKPDS - Intensive Glycemic Control Benefits

Study Design: UK Prospective Diabetes Study - randomized trial in 3,867 newly diagnosed Type 2 diabetics. Intensive vs conventional glucose control. Median follow-up: 10 years.

Results: Each 1% reduction in HbA1c associated with: 37% decrease in microvascular complications (p<0.0001), 21% reduction in diabetes-related deaths (p<0.01), 14% reduction in myocardial infarction (p=0.052). Intensive control (HbA1c 7.0% vs 7.9% conventional): 25% reduction in microvascular endpoints, 16% reduction in myocardial infarction (p=0.052). Retinopathy progression: 21% reduction with intensive control. Nephropathy development: 33% reduction. Legacy effect: Benefits persisted 10 years post-trial despite loss of HbA1c separation.

Conclusion: Intensive glycemic control early in disease course provides lasting benefits for complications prevention.

Citation: Stratton IM et al. BMJ. 2000 Aug 12;321(7258):405-12